I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 0.
EPS: As of FY2026 Q2, the actual value is USD -0.3, missing the estimate of USD -0.2902.
EBIT: As of FY2026 Q2, the actual value is USD -25.85 M.
Cash Position
As of June 30, 2026, Lexeo Therapeutics, Inc. reported cash, cash equivalents, and investments in marketable securities of $234.2 million, which is expected to provide an operational runway into 2028. This compares to $246.6 million in cash, cash equivalents, and investments in U.S. Treasury securities as of December 31, 2025.
Operating Expenses
Research and Development (R&D) Expenses
R&D expenses were $19.0 million for the three months ended June 30, 2026, an increase from $14.7 million for the same period in 2025. For the six months ended June 30, 2026, R&D expenses totaled $34.7 million, compared to $31.9 million for the six months ended June 30, 2025.
General and Administrative (G&A) Expenses
G&A expenses decreased to $9.0 million for the three months ended June 30, 2026, from $16.0 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, G&A expenses were $15.6 million, a decrease from $32.6 million for the six months ended June 30, 2025.
Total Operating Expenses
Total operating expenses were $28.0 million for the three months ended June 30, 2026, down from $30.7 million for the same period in 2025. For the six months ended June 30, 2026, total operating expenses were $50.4 million, compared to $64.5 million for the six months ended June 30, 2025.
Operating Loss
Lexeo Therapeutics, Inc. reported an operating loss of - $28.0 million for the three months ended June 30, 2026, an improvement from an operating loss of - $30.7 million for the three months ended June 30, 2025. For the six months ended June 30, 2026, the operating loss was - $50.4 million, compared to - $64.5 million for the six months ended June 30, 2025.
Other Income and Expense
Total other income and expense was $2.2 million for the three months ended June 30, 2026, compared to $4.6 million for the same period in 2025. This includes interest income of $2.2 million in Q2 2026, up from $1.3 million in Q2 2025, and a gain on long-term investment of $3.4 million in Q2 2025 which was not present in Q2 2026.
Net Loss
Net loss for the three months ended June 30, 2026, was - $25.9 million, or - $0.30 per share, an improvement from a net loss of - $26.1 million, or - $0.60 per share, for the three months ended June 30, 2025. For the six months ended June 30, 2026, the net loss was - $46.1 million, or - $0.55 per share, compared to - $58.8 million, or - $1.53 per share, for the six months ended June 30, 2025.
Balance Sheet Data (as of June 30, 2026)
Total assets were $254.9 million, total liabilities were $19.8 million, and total stockholders’ equity was $235.1 million.
Outlook and Guidance
Lexeo Therapeutics, Inc. anticipates its cash runway will extend into 2028, funding operations through the LX2006 pivotal study and Biologics License Application (BLA) submission. Topline data for LX2006 is expected in the second half of 2027, with a potential BLA submission in the first half of 2028. For LX2020, a 12-month data update for all high-dose participants is expected in the fourth quarter of 2026, alongside regulatory engagement with the FDA in 2026.